99066-76-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid is used as an active pharmaceutical ingredient for its antifungal, antitubercular, and antibacterial properties. It has demonstrated effective inhibition of the growth of certain microorganisms, making it a valuable asset in the development of new treatments for various infections.
Used in Anticancer Research:
In the field of oncology, 5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid is used as a potential therapeutic agent for the treatment of cancer. Its unique chemical structure allows for further research into its ability to target and combat cancer cells, offering new possibilities for cancer treatment.
Used in Diabetes Treatment:
5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid is also being investigated for its potential use in the treatment of diabetes. Its biological activities and chemical properties are being studied to understand its possible role in managing or treating this chronic disease, providing hope for new therapeutic approaches in diabetes care.

Upstream product

• 16691-25-1 ethyl 5-phenyl-1,3,4-oxadiazole-2-carboxylate 
• 60214-04-2 ethyl 2-(2-benzoylhydrazineyl)-2-oxoacetate 
• 613-94-5 benzoic acid hydrazide 

Downstream Products

• 98591-60-7 5-phenyl-1,3,4-oxadiazole-2-carbonyl chloride 

Relevant academic research and scientific papers

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

Synthesis, enzyme kinetics and computational evaluation of N-(β-d-glucopyranosyl) oxadiazolecarboxamides as glycogen phosphorylase inhibitors

All possible isomers of N-β-d-glucopyranosyl aryl-substituted oxadiazolecarboxamides were synthesised. O-Peracetylated N-cyanocarbonyl-β- d-glucopyranosylamine was transformed into the corresponding N-glucosyl tetrazole-5-carboxamide, which upon acylation